Q-omics provides the consensus-scored LINC01555 profile across patient tissues and cancer cell-line models. LINC01555 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC01555 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, LINC01555 RNA expression shows 8,290 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight HNSC, KIRC, and KIRP as cancer lineages where LINC01555 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01555 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01555 survival associations across molecular data types. LINC01555 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01555 RNA expression–survival associations across cancer types. High LINC01555 expression shows unfavorable associations in HNSC, DLBC, ACC and LIHC, but favorable associations in READ and OV. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC01555 RNA expression.
This table summarizes LINC01555 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01555. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01555 shows lower tumor expression in KIRC and KICH and higher tumor expression in COAD, BRCA, BLCA and HNSC. The KIRC box plot shows higher LINC01555 RNA expression in normal versus tumor tissue (log2 FC = −0.629, t-test p < 0.001).
This table shows molecular features associated with LINC01555 in patient tissues and cancer cell lines. In patient samples, LINC01555 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC01555 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
